Version 2 2020-01-17, 18:09Version 2 2020-01-17, 18:09
Version 1 2020-01-09, 18:37Version 1 2020-01-09, 18:37
journal contribution
posted on 2020-01-17, 18:09authored byTejas Navaratna, Lydia Atangcho, Mukesh Mahajan, Vivekanandan Subramanian, Marshall Case, Andrew Min, Daniel Tresnak, Greg M. Thurber
Chemically stabilized
peptides have attracted intense interest
by academics and pharmaceutical companies due to their potential to
hit currently “undruggable” targets. However, engineering
an optimal sequence, stabilizing linker location, and physicochemical
properties is a slow and arduous process. By pairing non-natural amino
acid incorporation and cell surface click chemistry in bacteria with
high-throughput sorting, we developed a method to quantitatively select
high affinity ligands and applied the Stabilized Peptide Evolution
by E. coli Display technique to develop disrupters
of the therapeutically relevant MDM2-p53 interface. Through in situ
stabilization on the bacterial surface, we demonstrate rapid isolation
of stabilized peptides with improved affinity and novel structures.
Several peptides evolved a second loop including one sequence (Kd = 1.8 nM) containing an i, i+4 disulfide bond. NMR structural determination
indicated a bent helix in solution and bound to MDM2. The bicyclic
peptide had improved protease stability, and we demonstrated that
protease resistance could be measured both on the bacterial surface
and in solution, enabling the method to test and/or screen for additional
drug-like properties critical for biologically active compounds.